During the third quarter of the year, Merck & Co., Inc. reported revenue of $10.33 billion. It also came in below Wall Street’s revenue estimate of $10.55 billion, which isn’t good news for MRK stock. Merck & Co., Inc. says that there were a few factors that caused its revenue for the third quarter of 2017 to decline. Among these reasons is the borrowing of GARDASIL 9 supplies by the U.S. Centers for Disease Control and Prevention Pediatric Vaccine Stockpile.
About The Author
JPMorgan becomes just seventh bank to cover Buffett’s Berkshire Hathaway, calling it a screaming buy
September 14, 2017
August 21, 2017
November 23, 2017